Extending expert Respiratory Clinical Research Services in USA, India and Europe with specialized trials, regulatory support, and patient-focused solutions.
We bring distinctive expertise to the design and execution of respiratory clinical research services, extending holistic support across multifaceted therapeutic areas in clinical research. With an integrated framework of scientific, regulatory, and operational capabilities, we provide sophisticated respiratory diagnostics and trial solutions for pharmaceutical, biologic, and medical device sponsors. Among prominent CRO companies, we specialize in developing novel respiratory therapies that address complex pulmonary pathologies across cross-border markets. From early-phase proof-of-concept trials to late-phase multicenter studies and real-world evidence generation, our end-to-end solutions ensure agility, exactness, and compliance at every key step of the clinical development lifecycle.
Specialized professionals with deep knowledge in pulmonary research and clinical trial execution.
From Phase 1 to 4 respiratory studies, ensuring accuracy, compliance, and global regulatory alignment.
Focused recruitment, retention, and monitoring strategies for diverse respiratory conditions.
Respiratory diseases ranging from chronic obstructive pulmonary disease (COPD), asthma, and idiopathic pulmonary fibrosis (IPF) to acute infections like pneumonia and COVID-19 pose significant challenges due to their variable pathophysiology, diagnostic complexity, and fluctuating clinical manifestations. Through our Respiratory Clinical Research Services, we combine deep therapeutic insight with real-time clinical intelligence to navigate these intricacies.Our multidisciplinary teams include pulmonologists, respiratory therapists, biomarker scientists, and regulatory strategists who collaboratively design protocols that meet stringent regulatory standards while maintaining patient-centric feasibility. Whether it involves bronchodilator reversibility testing, spirometry endpoints, imaging biomarkers, or wearable integration for oxygen saturation monitoring, our clinical design is always aligned with the latest scientific developments and health authority expectations.
We offer a full-spectrum service model across Phase 1 to 4 of respiratory drug and device development.
Regulatory foresight is embedded in every trial. Our regulatory affairs specialists collaborate with sponsors from the pre-IND stage through NDA/MAA submission, offering:
With growing demand for long-term effectiveness & pharmacoeconomic data, we offer robust RWE solutions in the respiratory domain. Through prospective observational studies, EMR data mining, patient registries, & pragmatic trials, we help sponsors demonstrate value-based outcomes & support label expansion strategies.
Our post-marketing safety surveillance programs monitor adverse events across large, diverse populations crucial for therapies with chronic use or pediatric applications. We also integrate patient-reported outcomes to capture real-world quality-of-life benefits. Our global network of investigators and data partners ensures high-quality evidence generation tailored to regional needs. By combining scientific expertise with advanced analytics, we empower sponsors to make informed regulatory and market access decisions.
Additionally, our tailored study designs address both payer and regulatory requirements. We provide end-to-end support from protocol development to publication-ready deliverables. With a focus on innovation and compliance, our RWE solutions accelerate product adoption and strengthen competitive positioning.
We support a wide range of indications across the respiratory spectrum, including but not limited to:
Extensive studies involving ICS, LABAs, biologics (anti-IL-5, anti-IgE), & precision-guided therapies for better disease control.
Full-scale programs assessing dual/triple drug regimens, novel inhalers, and behavioral interventions like smoking cessation.
Rare disease expertise with genomic profiling, custom protocols, and collaboration with global KOL networks.
Fast-track trials for antivirals, monoclonal antibodies, and respiratory support devices tailored for public health emergencies.
Development and surveillance of vasodilators, endothelin receptor antagonists, and prostacyclin-based therapies.
Investigational studies on antihistamines, leukotriene inhibitors, and intranasal steroids using validated PROs.
Trials on non-invasive neuromodulation, digital therapeutics, and wearable respiratory monitoring systems.
Respiratory Clinical Research Services support clinical trials focused on lung diseases such as asthma, COPD, pulmonary fibrosis, and rare respiratory disorders. Services include trial design, patient recruitment, biomarker studies, inhalation trials, data management, and regulatory compliance.
We conduct trials for a wide range of respiratory diseases including asthma, COPD, cystic fibrosis, interstitial lung disease (ILD), pulmonary fibrosis, and rare or pediatric respiratory conditions.
Our patient recruitment approach combines site networks, patient registries, digital outreach, and careful screening to ensure eligible participants are enrolled, improving retention and trial outcomes.
As a global CRO, we provide end-to-end services including protocol design, pulmonary function testing (PFT), inhalation drug delivery trials, biomarker analysis, imaging, safety monitoring, data management, and regulatory support.
We specialize in respiratory endpoints such as FEV1, DLCO, oscillometry, and cough monitoring. Biomarker studies, imaging, and central reading services are conducted to ensure precise, regulatory-compliant outcome assessment.
If you are planning to develop novel treatments in any therapeutic area, it’s time to consult a CRO that delivers rigor, efficiency, and regulatory clarity at every stage. Let’s position your therapy for global markets.
Be the first to know the latest trends in clinical research, real-world case studies, and industry secrets.
ProRelix Research is the rapidly growing Contract/ Clinical Research Organization (CRO) with multi-country service capability supporting phase 1, 2, 3, & 4 clinical trials of Pharma, Biotech, Biopharma, Medical Device, Nutraceutical & Herbal companies to conduct in the USA, India, Europe & South East Asia.
